

Title (en)  
APPLICATION OF KDM5A GENE AND ATRX GENE

Title (de)  
ANWENDUNG VON KDM5A-GEN UND ATRX-GEN

Title (fr)  
APPLICATION D'UN GÈNE KDM5A ET D'UN GÈNE ATRX

Publication  
**EP 3950961 A4 20230125 (EN)**

Application  
**EP 20777844 A 20200323**

Priority  
• CN 2020080579 W 20200323  
• CN 201910228411 A 20190325

Abstract (en)  
[origin: EP3950961A1] The present invention provides use of KDM5A gene and/or ATRX gene as biomarkers in evaluating the efficacy of Chlauranib or guiding the administration of Chlauranib, and use of Chlauranib for the manufacture of a drug for treating small cell lung cancer patients with gene mutations in KDM5A gene or ATRX gene.

IPC 8 full level  
**A61K 31/47** (2006.01); **A61P 35/00** (2006.01); **C12Q 1/6886** (2006.01)

CPC (source: CN EP KR US)  
**A61K 31/47** (2013.01 - EP KR US); **A61P 35/00** (2017.12 - EP KR US); **C12Q 1/6883** (2013.01 - KR); **C12Q 1/6886** (2013.01 - CN EP US); **G01N 33/57423** (2013.01 - CN EP KR US); **G01N 33/68** (2013.01 - CN); **C12Q 2600/106** (2013.01 - CN EP KR US); **C12Q 2600/156** (2013.01 - CN EP KR US); **G01N 2800/52** (2013.01 - EP)

Citation (search report)  
• [X] WO 2014062720 A2 20140424 - EPIZYME INC [US]  
• [X] WO 2016141169 A1 20160909 - CARIS MPI INC [US]  
• [X] GARRETT M FRAMPTON ET AL: "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", NATURE BIOTECHNOLOGY, vol. 31, no. 11, 20 October 2013 (2013-10-20), New York, pages 1023 - 1031, XP055511777, ISSN: 1087-0156, DOI: 10.1038/nbt.2696  
• [X] LUIS FELIPE CAMPESATO: "Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice - Supplementary Material", 1 October 2015 (2015-10-01), XP055611165, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741447/> [retrieved on 20190806], DOI: 10.18632/oncotarget.5950  
• [X] ILLUMINA ET AL: "TruSight? Oncology 500 A comprehensive next-generation sequencing assay that targets somatic variants, TMB, and MSI status from the same FFPE tumor only sample.", 9 January 2019 (2019-01-09), XP055664586, Retrieved from the Internet <URL:http://albiogen.ru/upload/iblock/8e6/8e66914c1b78f53509fe9186d80f8d75.pdf> [retrieved on 20200203]  
• [A] SEN TRIPARNA ET AL: "Targeting DNA damage repair in small cell lung cancer and the biomarker landscape", TRANSLATIONAL LUNG CANCER RESEARCH, vol. 7, no. 1, 1 February 2018 (2018-02-01), Hong Kong, pages 50 - 68, XP093009106, ISSN: 2218-6751, DOI: 10.21037/tlcr.2018.02.03  
• [A] ROMA-RODRIGUES CATARINA ET AL: "Targeting Tumor Microenvironment for Cancer Therapy", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 4, 15 February 2019 (2019-02-15), pages 840, XP093009115, DOI: 10.3390/ijms20040840  
• See references of WO 2020192606A1

Cited by  
EP3949966A4; AU2020248270B2

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 3950961 A1 20220209; EP 3950961 A4 20230125**; AU 2020246335 A1 20211118; BR 112021019155 A2 20220215; CA 3134620 A1 20201001; CN 111733235 A 20201002; JP 2022527895 A 20220607; KR 20210143866 A 20211129; MX 2021011677 A 20211022; TW 202035700 A 20201001; TW I798532 B 20230411; US 2022184056 A1 20220616; WO 2020192606 A1 20201001; ZA 202108165 B 20230628

DOCDB simple family (application)  
**EP 20777844 A 20200323**; AU 2020246335 A 20200323; BR 112021019155 A 20200323; CA 3134620 A 20200323; CN 2020080579 W 20200323; CN 202010211409 A 20200323; JP 2021557124 A 20200323; KR 20217034496 A 20200323; MX 2021011677 A 20200323; TW 109106184 A 20200226; US 202017442886 A 20200323; ZA 202108165 A 20211022